CP Cavendish v1

7/26/2019 CP Cavendish v1

http://slidepdf.com/reader/full/cp-cavendish-v1 1/20

Cavendish Global Health Impact For

October 25-28, 2015

Ed Addison,

Chairman, Co-Founder and CEO



ancreatic Cancer

People diagnosed50,000

Of all cancers in the!"

Of all cancer deaths US

#"

Will die frompancreaticcancer

$0,5%0

Key statistics for !"# from the American

Cancer Society$

Source$ American Cancer Society, %nc&

http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics





'argets pancreaticcancer

using real genomicsdata

Uses genome data aanalysis

to disco*er no*eltargets

(esigning drug leads for those targets

Findin& a Cure



Central 'ervous ()stem *ise

+lheimers

5.! millionAmericans

ha*e it2/! are+omen

+m)otrophic a

(clerosisProgressi*edegenerationof motor ner*ecells in therain and

spinal cord

(oes notimpair yourintellect orsenses

%thleading causeof death

Onl)

cause of

death in thetop "! inAmerica thatcant epre*ented,

slo+ed, orcured

%mpairs*oluntain*oluntmuscles

Often re

respiratfailure

Conside)%. as odisease

Source$ Al/heimer0s Association Source$ 'he 1ohns .op2ins Uni*ersity

http://www.alz.org/facts/#quickFacts


http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html






A% technology identi3esno*el targets y souring

pulished research enalingas2et trials

(esigns drug leads fotargets and 3lters fo

properties such as rain arrier

Findin& a Cure



Contains e*ery smmolecule to increa+ellness of peoplethe +orld, to pre*e

people from dyingrelie*e their pain asu5ering

he tric is to 3n

ri&ht ones

4irtual olecular (pace



Our ission

re-6uali3ed candidates enable us treduce cost, accelerate developmen

and tar&et elusive indications

Improve health and+ell-eingthrough therapid and

e6cientdesign of ne+medicines

*esi&n smallmoleculesthat inhiitprotein

targetsproduced ypathologies

+ppl) cloucomputingandcomputatiochemistry t

design drug



he ime is 'o7 or In (ilico

9h):• 7oores 8a+

• Accessiility of cloud-ased super computing

• Arti3cial intelligence

Ho7:• Store 9( model ofe*ery human protein inthe druggale genome

• Analy/e a proposeddrug for to:icity prior to

clinical trial

Emerging life sciencecenter



Collaoration

de*eloping

" drugs, *alidation

data

;rant for

de*elopment of

disco*ery methods

and select drugs

7uscle gro+th

and in<ammation

research

Autism and cancer research

Paid

7alaria

Collaoration

de*eloping= drug

programs

4aluable ;elationships



Ho7 do 7e *evelop edicinesChallen&in& *iseases:

%dentify the molecules+ith outstanding drug-li2e

properties that modulatethe acti*ity of proteintargets

• +ppl) the right technology• artner +ith *isionarycompanies

• Harness the trends of thedigital re*olution



+ppendi<Cloud Pharmaceuticals %n*estor O*er*ie+

Fall !"#



raditionaldiscover)has

Hi&h-throu&hputscreenin& is

imelinesand costso pastdevelopment e=orts

are

reviousin silicomethodsare

Low probabilityof success

Veryinecient

Prohibitive

Unreliable

RUG

ISCOVE

10,00

COMPOUN

PRE-CLINI

250

CLINICA

TRIALS

ACHIEVES F A

1

RUG

10

he Opportunit)



9hat 9e *o

•

Improve health and7ell-bein& through thecomputational designand rapid de*elopmentof ne+ therapies

•

(elect novel diseasetar&ets internally andthrough collaorations+ith uni*ersities,pharma, and iotechcompanies



Ho7 9e *o It>uantum olecular *esi&nrocess

• (esign compounds that inhiit the acti*ity of protein targets,

+hich are produced y the genes responsile for certainpathologies

• Comine high-performance cloud computing, >uantummechanics?molecular mechanics, and molecular property

simulation

• Fundamentally transform and impro*e the design of ne+medicines



9h) 9e +re ?etter

•

Computational chemistry po+ered ycloud computing helps streamline thedrug disco*ery process

• %t identi3es compounds that are ettersuited for de*elopment from the outset

• Pre-clinical de*elopment steps can then

e applied to a much more >uali3ed listof candidates

• 'his approach enales more rapidprogress at lo+er cost and a highersuccess rate, e*en +ith elusi*e targets



*emonstrated on an) *iseaar&ets•

We are uilding an e:tensi*eproduct pipeline that spans a+ide range of indicationsincluding$

• 8ipid 7etaolism

• Oncology

• @iruses

• %n<ammation

• Central ner*ous systemC)SB diseases

• Acti*ity demonstrated in

iological assays



Competitive +dvanta&es

•

Use of arti3cial intelligencesearches no*el molecular space toidentify the strongest matches toprotein targets, resulting in original%P and enormous di*ersity

• inding a6nity of molecules to

targets achie*es D! correlationusing >uantum chemistry, ma2ingour process *ery accurate

• iophysical models of chemicalproperties enales selection of*ery good drug candidates

harmacopia

'umate

@-herapeutics

4erseon

(chrodin&er

+

C C A

;

+

C B

* I 4 @ ; ( B

Competitive a



?usiness odel



9orld-Class ana&ement and?oard

@d +ddisonC@O

9 E:its: Entrepreneur

of the Gear

(hahar einan,h*C(O

ComputationalChemist,

(u2e Uni*ersity Post(oc

Well Pulished

a7rence Husic CIO

Chemist H %PAttorney

usiness 7odelE:pert

I Startups

Jo A7i2e

7

(a*

.aroJo

7arti 1e5

Chr

*on 4an *)eCOO

# Gears ofE:perience

Well Connected

io-%' ac2ground

)le ohme)er CFO

Former CFO H CEOAA% Pharma

Jaised o*er 9!!7

Pulic H Pri*ate

*ru&*evelopment

ana&er 'o e hired



>uestions:

@d +ddison, C@OCloud Pharmaceuticals %nc&L (a*is (ri*eJesearch 'riangle Par2, )C==!I

I"!B 9I-"!!ed&addisonMcloudpharmaceuticals&com

mailto:[email protected]




CP Cavendish v1

Documents

Transcript of CP Cavendish v1